Terms: = Lung cancer AND SEPT5, HCDCREL-1, 5413, ENSG00000184702, Q99719, PNUTL1, H5
20 results:
1. CCR5 promoter polymorphisms associated with nonsmall cell lung cancer.
Lu T; Shi Y; Wang M; Liu W; Cao Y; Shi L; Ma Q; Liu S
Int J Immunogenet; 2024 Feb; 51(1):10-19. PubMed ID: 37962280
[TBL] [Abstract] [Full Text] [Related]
2. Smoking-Induced M2-TAMs, via circEML4 in EVs, Promote the Progression of NSCLC through ALKBH5-Regulated m6A Modification of SOCS2 in NSCLC Cells.
Cheng C; Wang P; Yang Y; Du X; Xia H; Liu J; Lu L; Wu H; Liu Q
Adv Sci (Weinh); 2023 Aug; 10(22):e2300953. PubMed ID: 37246269
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network.
Xiao M; Pang C; Xiang S; Zhao Y; Wu X; Li M; Du F; Chen Y; Wang F; Wen Q; Xiao Z; Yang Z; Shen J
Sci Rep; 2023 Mar; 13(1):4311. PubMed ID: 36922519
[TBL] [Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
[TBL] [Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract] [Full Text] [Related]
6. Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France.
Grumberg V; Chouaïd C; Cotté FE; Jouaneton B; Jolivel R; Gaudin AF; Reynaud D; Assié JB; Borget I
J Med Econ; 2022; 25(1):691-699. PubMed ID: 35587018
[TBL] [Abstract] [Full Text] [Related]
7. A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies.
Scott JI; Mendive-Tapia L; Gordon D; Barth ND; Thompson EJ; Cheng Z; Taggart D; Kitamura T; Bravo-Blas A; Roberts EW; Juarez-Jimenez J; Michel J; Piet B; de Vries IJ; Verdoes M; Dawson J; Carragher NO; Connor RAO; Akram AR; Frame M; Serrels A; Vendrell M
Nat Commun; 2022 May; 13(1):2366. PubMed ID: 35501326
[TBL] [Abstract] [Full Text] [Related]
8. Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and cancer Consortium.
Elkrief A; Hennessy C; Kuderer NM; Rubinstein SM; Wulff-Burchfield E; Rosovsky RP; Vega-Luna K; Thompson MA; Panagiotou OA; Desai A; Rivera DR; Khaki AR; Tachiki L; Lynch RC; Stratton C; Elias R; Batist G; Kasi A; Shah DP; Bakouny Z; Cabal A; Clement J; Crowell J; Dixon B; Friese CR; Fry SL; Grover P; Gulati S; Gupta S; Hwang C; Khan H; Kim SJ; Klein EJ; Labaki C; McKay RR; Nizam A; Pennell NA; Puc M; Schmidt AL; Shahrokni A; Shaya JA; Su CT; Wall S; Williams N; Wise-Draper TM; Mishra S; Grivas P; French B; Warner JL; Wildes TM;
Lancet Healthy Longev; 2022 Mar; 3(3):e143-e152. PubMed ID: 35187516
[TBL] [Abstract] [Full Text] [Related]
9. Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance.
Ray P; Raghunathan K; Ahsan A; Allam US; Shukla S; Basrur V; Veatch S; Lawrence TS; Nyati MK; Ray D
J Biol Chem; 2020 Sep; 295(36):12661-12673. PubMed ID: 32669362
[TBL] [Abstract] [Full Text] [Related]
10. An Isoform of the Oncogenic Splice Variant AIMP2-DX2 Detected by a Novel Monoclonal Antibody.
Kim DG; Nguyen TTH; Kwon NH; Sung J; Lim S; Kang EJ; Lee J; Seo WY; Kim A; Chang YS; Shim H; Kim S
Biomolecules; 2020 May; 10(6):. PubMed ID: 32471182
[TBL] [Abstract] [Full Text] [Related]
11. Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis.
Zhong C; Lang Q; Yu J; Wu S; Xu F; Tian Y
Clin Exp Immunol; 2020 Apr; 200(1):12-21. PubMed ID: 31901178
[TBL] [Abstract] [Full Text] [Related]
12. EGFR may participate in immune evasion through regulation of B7‑H5 expression in non‑small cell lung carcinoma.
Dong Z; Zhang L; Xu W; Zhang G
Mol Med Rep; 2018 Oct; 18(4):3769-3779. PubMed ID: 30106102
[TBL] [Abstract] [Full Text] [Related]
13. Expression pattern of parkin isoforms in lung adenocarcinomas.
D'Amico AG; Maugeri G; Magro G; Salvatorelli L; Drago F; D'Agata V
Tumour Biol; 2015 Jul; 36(7):5133-41. PubMed ID: 25656612
[TBL] [Abstract] [Full Text] [Related]
14. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.
Janakiram M; Chinai JM; Fineberg S; Fiser A; Montagna C; Medavarapu R; Castano E; Jeon H; Ohaegbulam KC; Zhao R; Zhao A; Almo SC; Sparano JA; Zang X
Clin Cancer Res; 2015 May; 21(10):2359-66. PubMed ID: 25549724
[TBL] [Abstract] [Full Text] [Related]
15. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.
Li K; Tavaré R; Zettlitz KA; Mumenthaler SM; Mallick P; Zhou Y; Marks JD; Wu AM
Mol Cancer Ther; 2014 Nov; 13(11):2607-17. PubMed ID: 25143449
[TBL] [Abstract] [Full Text] [Related]
16. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
[TBL] [Abstract] [Full Text] [Related]
17. ATM sequence variants associate with susceptibility to non-small cell lung cancer.
Yang H; Spitz MR; Stewart DJ; Lu C; Gorlov IP; Wu X
Int J Cancer; 2007 Nov; 121(10):2254-9. PubMed ID: 17582598
[TBL] [Abstract] [Full Text] [Related]
18. Novel adenoviral vectors coding for GFP-tagged wtCFTR and deltaF508-CFTR: characterization of expression and electrophysiological properties in A549 cells.
Vais H; Gao GP; Yang M; Tran P; Louboutin JP; Somanathan S; Wilson JM; Reenstra WW
Pflugers Arch; 2004 Dec; 449(3):278-87. PubMed ID: 15452712
[TBL] [Abstract] [Full Text] [Related]
19. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation.
Dubray B; Henry-Amar M; Meerwaldt JH; Noordijk EM; Dixon DO; Cosset JM; Thames HD
Radiother Oncol; 1995 Sep; 36(3):211-7. PubMed ID: 8532908
[TBL] [Abstract] [Full Text] [Related]
20. Arylamine N-acetyltransferase activities in cell lines of mouse, rat, hamster and man differing in their sensitivity to 1,6-dinitropyrene.
Srivastava AK; Wiebel FJ
Toxicol Lett; 1990 Nov; 54(1):71-6. PubMed ID: 2244342
[TBL] [Abstract] [Full Text] [Related]
